Beste Oncology Times podcaster (2023)

O

Oncology Times - OncTimes Talk

1
Radicals Study Finds Adjuvant Radiotherapy No Benefit After Radical Prostatectomy 15:23

7d ago15:23

15:23

Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the 2023 annual congress of the European Society for Medical Oncology (ESMO) held i…

O

Oncology Times - OncTimes Talk

1
Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition 13:38

12d ago13:38

13:38

Research presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics found that a combination of two drugs targeting the nRAS mutation had clinical activity in patients with checkpoint-inhibitor refractory melanoma and had potential for treating other solid tumors with mutated nRAS as their oncogenic d…

O

Oncology Times - OncTimes Talk

1
Collagen-Bound Interleukin 12 Converts “Cold” Tumors into “Hot” Ones 14:50

12d ago14:50

14:50

Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That’s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC int…

O

Oncology Times - OncTimes Talk

1
Double TKI Therapy Improves Responses in MET Amplification-Driven EGFR-Mutant Non-Small Cell Lung Cancer 15:22

12d ago15:22

15:22

Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That’s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC internationa…

O

Oncology Times - OncTimes Talk

1
CLIC Protein Inhibition Key to Metformin’s Anti-Neoplastic Properties 24:17

13d ago24:17

24:17

The Chloride Intracellular Channel 1 (CLIC1) protein appears to hold the key to understanding the anti-proliferative action of metformin, according to laboratory evidence discussed at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in October 2023, in Boston. At the conference, Michele M. Mazzanti, PhD,…

O

Oncology Times - OncTimes Talk

1
Adjuvant ATR Inhibition Prolonged Life in Patients with Relapsed Small Cell Lung Cancer 18:59

15d ago18:59

18:59

Dr. Takahashi talks with OncTimes Talk’s Peter Goodwin about the Phase 2 study he presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11 - 15, 2023. Dr. Takahashi reported an improvement in median overall survival among patients with relapsed small cell lung cancer who had the ATR inhibitor…

O

Oncology Times - OncTimes Talk

1
Mitophagy Discovered as Potential Reason for AML’s Resistance to Venetoclax 15:20

15d ago15:20

15:20

Acute myeloid leukemia (AML) is notoriously difficult to treat. Only 28 percent of patients survive beyond 5 years after diagnosis. Mitophagy, a process in which damaged mitochondria are eliminated to prevent the transmission of death signals, has been identified as a key mechanism that allows leukemia cells to resist the effects of the widely pres…

O

Oncology Times - OncTimes Talk

1
Unintentional Bias of Breast Cancer Randomized Clinical Trial Interpretations Through Discontinuation Imbalance 11:54

3M ago11:54

11:54

Some of the big randomized clinical trials could lead to unintentional bias because of an imbalance of assigned treatment discontinuations between experimental and control arms, according to ASCO poster author Faris Tamimi, MD, at the University Health Network Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre. OncTimesT…

O

Oncology Times - OncTimes Talk

1
Trastuzumab Deruxtecan Benefits Patients with HER2-Low Metastatic Breast Cancer Irrespective of ER Expression 11:43

3M ago11:43

11:43

Although T-DXd had already been licensed for use in all categories of HER2 positivity, including patients with so-called HER2-low tumors (defined as having immunohistochemical score of 1+ or 2+ with non-amplified in-situ hybridization), doubts have remained about the effectiveness of this antibody drug conjugate in the subset of such patients who a…

O

Oncology Times - OncTimes Talk

1
Artificial Intelligence Model Predicts Overall Survival in Patients with Metastatic Breast Cancer 9:17

3M ago9:17

9:17

A mathematical study of real-world data from 27,855 women whose breast cancer was diagnosed between 2008 and 2020 has shown that a machine-learning artificial intelligence algorithm was able to predict mortality and could become a key weapon in the clinician’s armory when selecting therapies on the basis of predicted survival. Initial findings and …

O

Oncology Times - OncTimes Talk

1
Axillary Dissection in Older Women With Clinically Node-Negative Breast Cancer 9:17

4M ago9:17

9:17

Caution was expressed at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting about potential adverse effects from one form of breast cancer treatment de-escalation. A poster warns about risks from omitting axillary sentinel node surgery in older women. In this edition of OncTimesTalk correspondent Peter Goodwin hears about axillary…

O

Oncology Times - OncTimes Talk

1
Variability of Biological Parameters Between Tumor Biopsy & Surgical Samples in Breast Cancer Patients 8:16

4M ago8:16

8:16

A real-world study reported at the ESMO Breast Cancer 2023 Annual Congress identified a risk for inappropriate therapeutic decision-making resulting from an alarmingly high rate of false-negative tests coming from biopsy specimens looking for biological parameters such as PR and HER2. Study researchers at the University of Catania suggested tumor h…

O

Oncology Times - OncTimes Talk

1
Full Compliance With Adjuvant Endocrine Therapy Brings 15 Percent Superior Survival in Patients With Breast Cancer 3:42

4M ago3:42

3:42

Patients with breast cancer who complied fully with their adjuvant endocrine medication lived 15 percent longer than those who skipped doses, according to a huge real-world study coordinated from Tübingen University, in Baden-Württemberg, Germany, reported at the 2023 ASCO Annual Meeting. OncTimesTalk correspondent Peter Goodwin discusses the findi…

O

Oncology Times - OncTimes Talk

1
Being Obese & Overweight Reduces Efficacy of Extended Endocrine Therapy in HR+ Breast Cancer 14:17

4M ago14:17

14:17

Being overweight or obese can reduce the benefit of extending adjuvant breast cancer hormone therapy in women younger than 60 years, according to research from the DATA trial discussed at the European Society for Medical Oncology (ESMO) Breast Cancer 2023 Congress. Senna W.M. Lammers, MD, from Maastricht University Medical Centre in The Netherlands…

O

Oncology Times - OncTimes Talk

1
ASCO 2023: Neoadjuvant Pembrolizumab Brought Big Benefit in Early-Stage Non-Small Cell Lung Cancer with Heather A. Wakelee, MD, FASCO 11:05

5M ago11:05

11:05

Non-small cell lung cancer was one of the big topics at the 2023 ASCO Annual Meeting where Heather Wakelee, MD, FASCO, Professor of Medicine and Chief of the Division of Oncology at Stanford University in California, was overheard reminding a junior cancer doctor that the only adjuvant therapy for lung cancer had been chemotherapy just a couple of …

O

Oncology Times - OncTimes Talk

1
ASCO 2023: How AI Can Help Physicians Communicate with Dying Patients Better & Also Reduce Costs 7:14

5M ago7:14

7:14

End-of-life care for patients with cancer could be significantly improved while simultaneously reducing cost according to the findings of a study from the University of Pennsylvania. Ravi Parikh, MD, MPH, talks with OncTimesTalk correspondent Peter Goodwin about his findings on the value of harnessing AI to help doctors have serious illness convers…

O

Oncology Times - OncTimes Talk

1
Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD 5:30

5M ago5:30

5:30

Roy Herbst, MD PhD, Deputy Director of the Yale Cancer Center at Yale School of Medicine, talks with OncTimesTalk correspondent Peter Goodwin about his group’s findings from the international Phase III ADAURA clinical trial looking at adjuvant therapy with the anti EGFR-mutant drug osimertinib in patients with completely resected stage one B to thr…

O

Oncology Times - OncTimes Talk

1
Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD 11:04

5M ago11:04

11:04

Roy Herbst, MD PhD, Deputy Director of the Yale Cancer Center at Yale School of Medicine, talks with OncTimesTalk correspondent Peter Goodwin about his group’s findings from the international Phase III ADAURA clinical trial looking at adjuvant therapy with the anti EGFR-mutant drug osimertinib in patients with completely resected stage one B to thr…

O

Oncology Times - OncTimes Talk

1
Emerging Cancer Treatments for Esophageal Cancer with Brian Henick, MD 24:46

7M ago24:46

24:46

Progress in esophageal cancer is forging ahead at Columbia University in New York. Brian Henick, MD, is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract. As Associate Director of Experimental Therapeutics and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Henick…

O

Oncology Times - OncTimes Talk

1
Meet the New Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP 15:05

8M ago15:05

15:05

Today we are introducing the new Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP. In her new role, Graff will help Oncology Times continue to provide essential clinical news and analysis for the cancer care community.Graff is Director of Breast Oncology at Lifespan Cancer Institute and Assistant Professor of Medicine at Brown Uni…

O

Oncology Times - OncTimes Talk

1
Ravi B. Parikh, MD, on How Machine Learning-Triggered Reminders Can Improve End-of-Life Care for Cancer Patients 21:05

9M ago21:05

21:05

When cancer advances to an incurable stage, some patients may prioritize treatment that will extend their life as long as possible, and others may prefer a care plan that’s designed to minimize pain. Talking to patients about their prognosis and values can help clinicians develop care plans that are better aligned to each patient’s goals. However, …

O

Oncology Times - OncTimes Talk

1
Deanna Gerber, MD, on Navigating Cervical Cancer Screening 13:02

9M ago13:02

13:02

Despite increased screening and HPV vaccines, cervical cancer remains the fourth-leading cause of cancer death among women worldwide. Screening guidelines are constantly scrutinized and reassessed. The most current U.S. Preventative Services Task Force (USPSTF) guidelines recommend screening for cervical cancer every 3 years with cervical cytology …

O

Oncology Times - OncTimes Talk

1
January Research Review: Promising Results in HemOnc Clinical Trials 43:58

10M ago43:58

43:58

This episode is Research Review, a quarterly review of the research you may have missed. Today, we are covering the American Society of Hematology Annual Meeting highlights. First Up, results from the ECOG-ACRIN E1910 Randomized Phase III clinical trial showed that blinatumomab improved overall survival in newly diagnosed adult patients with b-line…

O

Oncology Times - OncTimes Talk

1
Unraveling a Complex Disease: Gary K. Schwartz, MD, on Sarcoma Research Highlights, Targeted Agents & Future Directions 30:06

11M ago30:06

30:06

Sarcoma represents an incredibly rare group of cancers comprised of 50 histologic subtypes, with approximately 13,000 new diagnoses per year. Each histologic type exhibits a unique biologic behavior, and, as such, prognosis and optimal treatment strategies vary. Sarcoma can appear anywhere in the body, and local invasion of nearby organs may make s…

O

Oncology Times - OncTimes Talk

1
ASH 2022: David Sallman, MD, Discusses Positive Phase I Dose Escalation Data for PRGN-3006 UltraCAR-T in AML Patients 17:52

11M ago17:52

17:52

A study using chimeric antigen receptor (CAR)-T cells has proven to be safe for treating patients with relapsed or refractory acute myeloid leukemia (AML). The agent known as PRGN-3006 also brought remissions among patients who had chemotherapy for lymphodepletion prior to their CAR-T cell procedure (Abstract 4633). After the lead author of the new…

O

Oncology Times - OncTimes Talk

1
Anil K. Rustgi, MD, on the Current State of Colorectal Cancer Screening 24:47

1y ago24:47

24:47

Colorectal cancer is the third most diagnosed cancer and the second leading cause of cancer deaths worldwide. The current gold standard for screening, the colonoscopy, reduces cancer deaths by 67 percent, according to a 2018 study from Kaiser Permanente. So, we know screening is effective. However, obstacles remain. Colonoscopies are invasive and c…

O

Oncology Times - OncTimes Talk

1
Small Bytes: Phase I Study Finds Pan-AKT Inhibitor Ipatasertib Safe & Effective, Featuring Carolyn McCourt, MD 10:51

1y ago10:51

10:51

BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor—the investigational drug ipatasertib—in a Phase I study reported at the 2022 EORTC—NCI—AACR symposium on Molecular Targets and Cancer Therapeutics. Nearly a quarter of the patients treated with the AKT blocker had their tumors …

O

Oncology Times - OncTimes Talk

1
Small Bytes: How ctDNA Liquid Biopsies Can Detect Myeloid Malignancies & Occult Tumors 11:25

1y ago11:25

11:25

BARCELONA, Spain—Liquid biopsies are increasingly used to identify cancer progression and could also provide molecular evidence of higher risk for hematologic malignancies and solid tumors, according to findings from a study of circulating tumor DNA reported at the European Organization for Research and Treatment of Cancer—National Cancer Institute…

O

Oncology Times - OncTimes Talk

1
Dr. Lisa Newman on Eliminating Racial Disparities in Breast Cancer 25:46

1y ago25:46

25:46

In oncology today, there is an urgent need to better understand the implications of racial bias and disparities on the health outcomes of patients. Although breast cancer mortality rates decreased by 43 percent from 1989 to 2020, Black women remain more likely to die from breast cancer compared with White women, according to the 2022 American Cance…

O

Oncology Times - OncTimes Talk

1
HemOnc Highlights: Dr. Naveen Pemmaraju on the Benefits of Tagraxofusp for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm 14:56

1y ago14:56

14:56

We talk to Naveen Pemmaraju, MD, about the results of the largest prospective BPDCN trial evaluating the CD123-targeted therapy tagraxofusp in adults with treatment-naive and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN is a rare and aggressive myeloid malignancy of the dendritic cell lineage which can affect othe…

O

Oncology Times - OncTimes Talk

1
5 Questions on Making Cardio-Oncology More Accessible to Diverse Patient Populations with Dr. Sandeep Mittan 14:22

1y ago14:22

14:22

Today on OncTimes Talk, we are getting to know a clinical researcher in 5 questions. We sat down with Sandeep Mittan, PhD, FAHA, who is a Clinical Scientist in the Division of Women’s Health and Medical Oncology at the Montefiore Medical Center and The University Hospital for Albert Einstein College of Medicine in New York. His work investigates me…

O

Oncology Times - OncTimes Talk

1
ESMO 2022: For Desmoid Tumor, First Proven Therapy Shows Clear Benefit, “Should Become Standard” 9:22

1y ago9:22

9:22

PARIS, France—One of the most prominent late-breaking abstracts reported at ESMO 2022 in Paris was about a rare cancer, desmoid tumor, for which no standard therapy had yet been recommended and for which there had been a clear unmet need. A team from Germany presented new findings from a randomized study using nirogacestat, a “NOTCH inhibitor”—gamm…

O

Oncology Times - OncTimes Talk

1
ESMO 2022: PATHFINDER Presents Screening Paradigm Shift with A Blood Test to Facilitate Early Detection 10:17

1y ago10:17

10:17

The availability of a blood test for circulating DNA that can be used widely in healthy individuals to check for molecular signs of multiple cancers led Deb Schrag, MD, MPH, formerly of the Dana-Farber Cancer Center in Boston and currently Chair of the Department of Medicine at Memorial Sloan-Kettering Cancer Center, New York, to research it's use …

O

Oncology Times - OncTimes Talk

1
OncTimes Talk Research Review August 2022: Focus on Breast Cancer 46:01

1+ y ago46:01

46:01

Journalist Peter Goodwin gives OncTimes Talk a whirlwind review of the top 2022 breast cancer research as he reports live in person from the 2022 ESMO Berlin meeting. Featuring the following interviews with leading experts: 1. Patient-Reported Outcomes Support First-Line Pembrolizumab in TNBC: David Cescon, MD, PhD, Medical Oncologist and Clinician…

O

Oncology Times - OncTimes Talk

1
Metastatic Hormone-Sensitive Prostate Cancer: Extending Life By Adding a Third Drug to Standard Regimens with Dr. Vincent Khoo 17:14

1+ y ago17:14

17:14

In this edition of OncTimes Talk we’re taking a look at: extending life in patients with metastatic hormone-sensitive prostate cancer by adding a third drug to standard two-drug regimens. In the randomized Phase III ARASENS trial—just published in the New England Journal of Medicine—the androgen receptor inhibitor, darolutamide, was compared with p…

O

Oncology Times - OncTimes Talk

1
Liquid Biopsy ctDNA Prediction of Lung Cancer Relapse “Ready for Prime Time” 27:55

1+ y ago27:55

27:55

CAMBRIDGE, UK—OncTimesTalk visits genetics pioneer Nitzan Rosenfeld PhD, group leader at the Cancer Research UK Cambridge Institute, University of Cambridge, to learn about giant steps forward for lung cancer management—reported in the Annals of Oncology—made with the sensitive assay for circulating tumor DNA (ctDNA) they developed (2022; https://d…

O

Oncology Times - OncTimes Talk

1
ASCO 2022 Small Bytes Episode 3: Dr. Marla Lipsyc-Sharf on Personalized ctDNA Testing in Late, HR+, HER2-Negative Breast Cancer 10:16

1+ y ago10:16

10:16

At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin interviewed Marla Lipsyc-Sharf, MD, Medical Oncology Fellow at Dana-Farber Cancer Institute/Mass General Brigham, who reported what she believes is the first data on ctDNA detection in late adjuvant, hormone receptor-positive breast cancer. The research showed ctDNA testing was …

O

Oncology Times - OncTimes Talk

1
ASCO 2022 Small Bytes Episode 2: Dr. Julia C. Tchou on Telehealth Weight Loss Program for Breast Cancer Survivors 9:31

1+ y ago9:31

9:31

At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin caught up with Julia C. Tchou, MD, PhD, FACS, from the University of Pennsylvania Health System, during her poster session. Her research examined the feasibility and acceptability of a weight loss group program via telehealth for breast cancer survivors.…

O

Oncology Times - OncTimes Talk

1
ASCO 2022 Small Bytes: Dr. Alexander I. Spira on KRYSTAL-1 for Patients with Advanced/Metastatic NSCLC 6:13

1+ y ago6:13

6:13

At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin caught up with Alexander I. Spira, MD, PhD, FACP after his presentation on KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation (Abstract 9002).…

O

Oncology Times - OncTimes Talk

1
Colleague Conversations: A Look at Germline Predisposition to Hematologic Malignancies 18:42

1+ y ago18:42

18:42

Colleague Conversations offers insights into hematology/oncology from two different perspectives: a seasoned hematologist/oncologist and a clinician earlier in their career. Oncology Times reporter Catlin Nalley sat down with Lucy A. Godley, MD, PhD, and Gina Keiffer, MD, to discuss germline predisposition to hematologic malignancies. They delve in…

O

Oncology Times - OncTimes Talk

1
Refugees & Cancer Care: Ukraine, Lebanon & Beyond Featuring Dr. Richard Sullivan & Dr. Deborah Mukherji 34:15

1+ y ago34:15

34:15

As Russian forces continue to bombard Ukraine, concerns are mounting about the most vulnerable citizens there, including the ill and those with cancer. Today on OncTimes Talk, we review the war in Ukraine and discuss how the war is impacting cancer patients and health systems in neighboring countries. Trying to process the refugee flow is very daun…

O

Oncology Times - OncTimes Talk

1
Unpacking the Role of Emotions in Mastectomy Decisions with Clara N. Lee, MD 22:24

1+ y ago22:24

22:24

A bilateral prophylactic mastectomy for women at high risk of developing breast cancer can reduce their risk of developing the disease by up to 90 percent, according to the National Cancer Institute. An increasing number of women, including young women, are taking up this option. And while the data shows mastectomy is an effective method of reducin…

O

Oncology Times - OncTimes Talk

1
Mitigating the Effects of Climate Change on Cancer Care With Robert A. Hiatt, MD, PhD 15:08

1+ y ago15:08

15:08

While the threat of climate change may conjure images of sea level rise, extreme weather patterns, and drought, the full picture of how climate change will impact oncology practice and care is still emerging. We do know that climate change will impact cancer risk, increase exposure to carcinogens, impede access to care, and ultimately effect surviv…

O

Oncology Times - OncTimes Talk

1
Roswell Park’s Candace S. Johnson & Congressman Brian Higgins on the Promise of Biden’s Cancer Moonshot 14:01

1+ y ago14:01

14:01

In early February, President Joe Biden announced that he is supercharging the Cancer Moonshot program to accelerate progress against cancer and save lives. The ambitious, jumpstarted Cancer Moonshot aims to reduce the U.S. death rate due to cancer by at least 50 percent over the next 25 years, and to improve the lives of all Americans living with a…

O

Oncology Times - OncTimes Talk

1
ASH 2021 Revisited: Plenary Sessions, ZUMA-7 & COVID Vaccines 41:47

2y ago41:47

41:47

Today we revisit three studies presented at the ASH 2021 Annual Meeting. Primary Analysis of ZUMA-7 The 2021 American Society of Hematology Plenary Sessions in Atlanta, Georgia, heard data from a new study of CAR-T cell therapy in patients with diffuse large B-cell lymphoma: the Phase III randomized ZUMA-7 trial. This compared Axicabtagene Ciloleuc…

O

Oncology Times - OncTimes Talk

1
OncTimes Talk Research Review February 2022: Dr. Stephen Hahn, COVID, 2021 World Cancer Leaders’ Summit & Cervical Cancer News 1:06:19

2y ago1:06:19

1:06:19

Today we are bringing you a round up of three stories from around the world. We will start at the 2021 World Cancer Leader’s Summit, then move onto a story on how radiotherapy can cut late gastrointestinal toxicity for cervical cancer patients, and finish with lessons on what COVID has taught us about cancer care. All interviews are brought to you …

O

Oncology Times - OncTimes Talk

1
ASH 2021 Recap: COVID-19 in Patients with Acute Leukemias & Myelodysplasia In Conversation with Dr. Pinkal Desai 18:41

2y ago18:41

18:41

At the 2021 Annual Meeting of the American Society of Hematology, researchers presented more data on additional risks faced by patients who have acute leukemia or myelodysplastic syndrome and have become infected with COVID-19. In a key study presented at ASH, Dr. Pinkal Desai from New York’s Weill Cornell Medical College has identified clinical pr…

O

Oncology Times - OncTimes Talk

1
ASH 2021 Recap: Multi Omics Sheds New Light on Malignant Transformation from Myeloproliferative Neoplasm to AML 17:53

2y ago17:53

17:53

In this episode, we bring you new research from the 2021 American Society of Hematology Annual Meeting about the cellular processes involving the mutated TP53 oncogene that can convert a patient’s—fairly benign—myeloproliferative neoplasm into a very threatening acute myeloid leukemia. These have been under investigation at Oxford University in the…

O

Oncology Times - OncTimes Talk

1
Study Recap: After 6 Months, Pfizer COVID Vaccine Remains Effective Against Hospitalizations 14:49

2y ago14:49

14:49

A new study provides support for high effectiveness of the Pfizer COVID vaccine against hospital admissions up until around 6 months after being fully vaccinated. The real-world, retrospective cohort study included data from 3.4 million Californian residents and was recently published in The Lancet. The importance of this Californian study is that …

O

Oncology Times - OncTimes Talk

1
Research Spotlight: MET Amplification as Driver for NSCLC 16:52

2y ago16:52

16:52

A new study has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC). The paper, titled “Crizotinib in Patients With MET-Amplified NSCLC,” published in the Journal of Thoracic Oncology, introduces a third means of defining NSCLC subsets that can be targeted with a specific drug. In th…

Podcaster verdt å lytte til

Oncology Times Podcaster

Podcaster verdt å lytte til

Hurtigreferanseguide